Roland Berger and KPMG advise Bridgepoint on Swedish deal
Alternative asset fund management group Bridgepoint has taken a minority stake in Diagnostiskt Centrum Hud, a provider of medical dermatology services in Sweden.
With the backing of the financial investor, Diagnostiskt Centrum Hud aims to accelerate its growth in Sweden and the Nordics, said the firm’s chief executive officer Philip Jerlmyr.
“We are excited to partner with Bridgepoint in the next stage of our expansion and further build the best dermatology provider across the Nordics together with our colleagues,“ he said.
Founded in 2012 by Philip Jerlmyr and three dermatologists, Stockholm-based Diagnostiskt Centrum Hud is a provider of medical dermatology services focused on treating melanoma, psoriasis and other severe dermatology conditions. The company has grown its team to around 35 professionals, and is one of the more well-known players in the local dermatology market.
Facing a growing market – key drivers include an aging population and an increase in the incidence of skin diseases such as skin cancer – the company’s management team has set its sights on expanding its capacity and geographic footprint. “Today we operate six clinics across four Swedish cities. The funding will enable us to roll out and acquire new clinics in Sweden and across the Nordic region,” said Jerlmyr.
Buyer Bridgepoint, which focuses on the mid-market segment, was advised during the transaction by M&A advisors from Roland Berger (commercial due diligence), KPMG (financial and tax consultancy) and Vinge (legal advisory).
Ann Dahlman, a partner at Bridgepoint responsible for Nordic investments, welcomed Diagnostiskt Centrum Hud to its portfolio. “We are very impressed by DCH’s successful expansion to-date and we look forward to supporting the team to realise its next phase of expansion.”
Meanwhile, at the other side of the deal table, Grant Thornton provided financial and tax advice, and Swedish law firm AG Advokat provided legal support.